I. COMMENCED TRADING IN AUGUST | ||||||||
Company |
Date |
Date Comm. |
Shares/Units (M) |
Price | Shares Out (M)% |
Lead, Other Underwriters | Gross (M) |
Post-Offering Market Cap (M)@ |
INITIAL OFFERINGS | ||||||||
There were no initial public offerings conducted in August. | ||||||||
OVERALLOTMENT OPTIONS EXERCISED | ||||||||
BioDelivery Sciences International Inc. (BDSIU)(1) |
11/2002 |
8/14/02 |
0.085U |
$5.25 |
7.085 |
Kashner Davidson Securities Roan Meyers Assoc. |
$0.446 |
N/A |
Total: $0.446M | ||||||||
Number of IPOs in August: 0 | ||||||||
Average value of August IPOs: $0M | ||||||||
Number of IPOs in 2002: 4 | ||||||||
Total raised in IPOs in 2002: $464.7M* | ||||||||
Average value of IPOs in 2002: $116.19M* | ||||||||
* Figures include an overallotment option exercised in January as part of a 2001 IPO. | ||||||||
Figures do not include an IPO conducted in June by YM BioSciences Inc. because the shares were privately placed. | ||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
% This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
@ Market capitalization calculated is based on the offering price. | ||||||||
(1) BioDelivery raised an additional $446,250 when Kashner Davidson Securities Corp. decided to partially exercise the underwriters' overallotment option in an amount equal to 85,000 shares of common stock and 85,000 redeemable Class A warrants. The money is in addition to the $10.5M raised in the company's IPO held in June. | ||||||||
FOLLOW-ON OFFERINGS | ||||||||
Company (Symbol) |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price | Shares Out (M) |
Lead, Other Underwriters | Gross (M) |
Post-Offering Market Cap (M) |
There were no follow-on offerings conducted in August. | ||||||||
Total: $0M | ||||||||
Number of follow-on offerings in August: 0 | ||||||||
Average value of August follow-ons: $0M | ||||||||
Number of follow-on offerings in 2002: 15 | ||||||||
Total raised in follow-ons in 2002: $529.93M | ||||||||
Average value of follow-ons in 2002: $35.33M | ||||||||
II. FILED AND PENDING | ||||||||
Company (Symbol/Proposed Symbol)#* |
Date Filed |
Shares/Units (M) |
Price Range |
Shares Out (M)% |
Lead, Other Underwriters |
Value (M) |
INITIAL OFFERINGS | ||||||
Corcept Therapeutics Inc. (CORT)(1) |
12/21/01 |
4S | $14-16 |
23.9 |
U.S. Bancorp Piper Jaffray (co-lead) CIBC World Markets (co-lead) Thomas Weisel Partners |
$60 |
DiaDexus Inc. (DDXS)(2) |
11/20/00 | 7S |
$12-14 |
31.1 | Lehman Brothers CIBC World Markets Robertson Stephens Fidelity Capital Markets |
$91 |
MitoKor Inc. (MITO)(3) |
3/8/02 | N/A |
N/A |
N/A | RBC Capital Markets Lazard Freres Legg Mason Wood Walker Gerard Klauer Mattison |
$60 |
Novirio Pharmaceuticals Ltd. (IDIX)(4) |
4/12/02 | N/A |
N/A |
N/A | Goldman Sachs (co-lead) Banc of America Securities (co-lead) JP Morgan Securities U.S. Bancorp Piper Jaffray |
$115 |
Protarga Inc. (PRTG)(5) |
12/12/01 | N/A |
N/A |
N/A | UBS Warburg (co-lead) U.S. Bancorp Piper Jaffray (co-lead) |
$75 |
Stem Genetics Inc. (N/A)(6) |
7/18/02 | 1.5S |
$7 |
32.3 | Self-underwritten |
$10.5 |
ViaCell Inc. (VIAC)(7) |
1/30/02 | N/A |
N/A |
N/A | UBS Warburg Banc of America Securities U.S. Bancorp Piper Jaffray |
$115 |
FOLLOW-ON OFFERINGS | ||||||
Advanced Tissue Sciences Inc. (ATIS)(8) |
6/12/02 | 10S |
$1.07 |
N/A | N/A |
$10.7 |
Antigenics Inc. (AGEN)(9) |
6/13/02 | N/A |
N/A |
33.1 | N/A |
$100 |
Aphton Corp. (APHT)(10) |
7/8/02 | 5S |
$6.50 |
25.1 | N/A |
$32.5 |
Ariad Pharmaceuticals Inc. (ARIA)(11) |
1/9/02 | 3S |
$5.28 |
35.4 | N/A |
$15.84 |
Biomira Inc. (Canada; BIOM; TSE:BRA)(12) |
5/2/02 | N/A |
N/A |
N/A | N/A |
C$150 (US$97.84) |
Biosante Pharmaceuticals Inc. (BISP)(13) |
5/6/02 | N/A |
N/A |
N/A | Self-underwritten |
$10 |
Celgene Corp. (CELG)(14) |
12/21/01 | N/A |
N/A |
75.6 | N/A |
$500 |
Cell Pathways Inc. (CLPA)(15) |
2/7/01 | N/A |
N/A |
N/A | N/A |
$25 |
Cepheid Inc. (CPHD)(16) |
12/21/01 | N/A |
N/A |
26.56 | N/A |
$35 |
Cerus Corp. (CERS)(17) |
8/13/01 | N/A |
N/A |
15.7 | N/A |
$300 |
CollaGenex Pharmaceuticals Inc. (CGPI)(18) |
10/26/01 | 0.965S |
$8.01 |
N/A | Kingsbridge Capital Prentice Securities |
$7.7 |
Cytogen Corp. (CYTO)(19) |
10/26/01 | 10S |
$2.50 |
79.8 | N/A |
$25 |
Dyax Corp. (DYAX)(20) |
4/25/02 | 5S |
$3.66 |
19.6 | N/A |
$18.3 |
EntreMed Inc. (ENMD)(21) |
5/10/02 | N/A |
N/A |
N/A | N/A |
$50 |
Exelixis Inc. (EXEL)(22) |
7/30/01 | N/A |
N/A |
49.2 | N/A |
$150 |
Genaera Corp. (GENR)(23) |
11/21/01 | N/A |
N/A |
38.9 | N/A |
$50 |
Genaissance Pharmaceuticals Inc. (GNSC)(24) |
10/18/01 | N/A |
N/A |
22.8 | N/A |
$35 |
Geron Corp. (GERN)(25) |
1/30/02 | N/A |
N/A |
N/A | N/A |
$150 |
Hollis-Eden Pharmaceuticals Inc. (HEPH)(26) |
2/26/02 | 3S |
$8.71 |
N/A | N/A |
$26.13 |
InSite Vision Inc. (AMEX:ISV)(27) |
2/2/01 |
N/A |
N/A |
N/A | Ladenburg Thalmann (placement agent) |
$40 |
Myriad Genetics Inc. (MYGN)(28) |
11/9/01 | N/A |
N/A |
N/A | N/A |
$250 |
NeoTherapeutics Inc. (NEOT)(29) |
1/3/01 | N/A |
N/A |
26.9 | N/A |
$50 |
Neurogen Corp. (NRGN)(30) |
8/16/02 | N/A |
N/A |
N/A | N/A |
$75 |
Northwest Biotherapeutics Inc. (NWBT)(31) |
6/4/02 | 11S |
$3.77 |
17 | C.E. Unterberg, Towbin |
$41.5 |
NPS Pharmaceuticals Inc. (NPSP)(32) |
1/7/02 | N/A |
N/A |
N/A | N/A |
$250 |
Pharmos Corp. (PARS)(33) |
2/4/02 | N/A |
N/A |
56.6 | N/A |
$25 |
SciClone Pharmaceuticals Inc. (SCLN)(34) |
11/6/01 | N/A |
N/A |
N/A | N/A |
$20 |
StemCells Inc. (STEM)(35) |
3/8/02 | 15S |
N/A |
N/A | N/A |
$37.8 |
Targeted Genetics Corp. (TGEN)(36) |
12/13/01 | 8.84S |
$2.57 |
N/A | N/A |
$22.72 |
Telik Inc. (TELK)(37) | 6/3/02 |
N/A |
N/A | 27.8 |
N/A |
$100 |
Trimeris Inc. (TRMS)(38) |
8/23/02 | 2S |
$48.29 |
20.8 | Morgan Stanley & Co. (co-lead) Goldman, Sachs & Co. (co-lead) Lehman Brothers Banc of America Securities |
$96.58 |
Tularik Inc. (TLRK)(39) |
8/14/01 | N/A |
N/A |
49.2 | N/A |
$250 |
III. WITHDRAWN AND POSTPONED | ||||||
Company (Symbol/Proposed Symbol)#* |
Date Filed/ Date Pulled |
Shares/Units (M) |
Price Range |
Shares Out (M) |
Lead, Other Underwriters |
Value (M) |
INITIAL OFFERINGS | ||||||
Aderis Pharmaceuticals Inc. (ADPX)(40) |
1/11/02- 8/8/02 |
5.5S |
$9-11 |
N/A |
UBS Warburg (co-lead) CIBC World Markets (co-lead) RBC Capital Markets Gerard Klauer Mattison |
$55 |
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. | ||||||
% This column reflects the shares outstanding following the offering, when disclosed. | ||||||
N/A = Not available, applicable or reported. | ||||||
AMEX = American Stock Exchange; TSE = Toronto Stock Exchange | ||||||
(1) Corcept's offering is for 4.5M shares, 4M sold by the company and 500,000 sold by a selling stockholder. The value of Corcept's offering, $60M, is based on the sale of 4M shares at $15 each, the midpoint of the expected price range. | ||||||
(2) DiaDexus' IPO value, $91M, is based on the sale of 7M shares at $13 each, the midpoint of the expected price range. The underwriters have an overallotment option on 1.05M shares. | ||||||
(3) MitoKor filed for an IPO to raise $60M. | ||||||
(4) Novirio filed for an IPO to raise $115M. | ||||||
(5) Protarga filed for an IPO with hopes of raising $75M. It did not disclose the number of shares to be offered or the expected price range. | ||||||
(6) Stem Genetics filed for an IPO to raise $10.5M. It intends to go public on the Over-the-Counter Bulletin Board, but did not specify a proposed symbol in its SEC filing. | ||||||
(7) ViaCell filed for a $115M IPO. No further details were disclosed. | ||||||
(8) Advanced Tissue filed a shelf registration statement with the SEC to issue up to 10M shares of its common stock. The value, $10.7M, is based on the June 12 closing stock price of $1.07. | ||||||
(9) Antigenics filed a shelf registration statement covering the issuance of common and preferred stock, as well as secured and unsecured debt securities, up to $60M. It also had a previous registration with $40M in securities remaining. | ||||||
(10) Aphton filed a shelf registration statement to sell up to 5M shares at a maximum amount of $6.50 per share. | ||||||
(11) Ariad filed a shelf registration statement to sell up to 3M shares. At the Jan. 8 closing stock price, it would raise $15.84M. | ||||||
(12) Biomira filed for a $150M shelf prospectus in Canada. | ||||||
(13) BioSante filed for a proposed self-underwritten offering of up to $10M in shares of common stock. | ||||||
(14) Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M. | ||||||
(15) Cell Pathways filed a shelf registration statement for the sale of $25M in common stock. | ||||||
(16) Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants. | ||||||
(17) Cerus filed to sell up to $300M of common stock and debt in a shelf offering. | ||||||
(18) The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01. CollaGenex privately placed 119,335 shares in May, raising $1M. It placed 32,187 shares in June, raising $266,667. | ||||||
(19) Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration statement. It privately placed 3M shares in January, and another 4.17M shares in June. | ||||||
(20) Dyax filed a shelf registration statement to sell up to 5M shares. The value, $18.3M, is based on the April 24 closing stock price, $3.66. | ||||||
(21) EntreMed filed a $50M shelf registration statement, allowing it to offer securities from time to time in the form of common stock, preferred stock or warrants to purchase securities. | ||||||
(22) Exelixis filed a shelf registration statement to sell up to $150M in common stock. | ||||||
(23) Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock. It privately placed $16.5M in shares in April. | ||||||
(24) Genaissance filed a shelf registration statement to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M. | ||||||
(25) Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants. | ||||||
(26) Hollis-Eden filed a shelf registration statement to sell up to 3M shares and warrants from time to time. The value is based on the proposed maximum offering price. | ||||||
(27) InSite filed a shelf registration statement in February 2001 to sell $40M in stock. | ||||||
(28) Myriad filed a shelf registration statement for the sale of up to $250M of various types of securities. | ||||||
(29) NeoTherapeutics filed a shelf registration statement covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. In May 2001, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. In November, it placed 950,000 shares, raising $3.8M. In December, it placed 0.77M shares, raising $2.95M. In March 2002, it raised $8.05M in a private placement. In June, it raised $1.66M in a private placement. In July, it raised $1.1M in a private placement. | ||||||
(30) Neurogen filed for a $75M universal shelf registration statement. | ||||||
(31) Northwest expects to offer 11M shares as part of a lock-up agreement with the underwriter from the company's December initial public offering. The value, $41.5M, is based on the June 3 closing stock price of $3.77. | ||||||
(32) NPS filed a shelf registration statement to offer and sell up to $250M of common stock, preferred stock and debt securities. | ||||||
(33) Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants. | ||||||
(34) SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering. SciClone privately placed $10.62M in shares in June. | ||||||
(35) StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed. | ||||||
(36) Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22 closing stock price of $2.57. | ||||||
(37) Telik filed a shelf registration statement to sell $100M in common stock, preferred stock, debt securities and warrants. | ||||||
(38) Trimeris' offering value, $96.58M, is based on an estimated maximum price per share of $48.29. The underwriters also have an overallotment option for 300,000 shares. | ||||||
(39) Tularik filed to sell up to $250M in common stock and debt securities. | ||||||
(40) Aderis withdrew its IPO due to unfavorable market conditions. | ||||||